Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 87,014 | -187,353 | -152,992 | -104,679 | -58,744 |
| Depreciation Amortization | 1,509 | 1,229 | 815 | 674 | 378 |
| Accounts receivable | -825 | -2,599 | -143 | 18,000 | -18,000 |
| Accounts payable and accrued liabilities | -3,001 | -249 | 1,614 | -408 | 1,485 |
| Other Working Capital | -12,111 | -11,437 | -2,650 | 14,308 | -16,070 |
| Other Operating Activity | 34,919 | 39,540 | 28,848 | 2,043 | 28,803 |
| Operating Cash Flow | $107,505 | $-160,869 | $-124,508 | $-70,062 | $-62,148 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,551 | -1,931 | -2,464 | -1,241 | -1,024 |
| Investing Cash Flow | $-1,551 | $-1,931 | $-2,464 | $-1,241 | $-1,024 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 288 | 392,275 | 179,050 | 120,396 | 28,550 |
| Common Stock Repurchased | -375,000 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -3,758 | -454 | -94 | -87 | 0 |
| Financing Cash Flow | $-378,470 | $391,821 | $178,956 | $120,309 | $28,550 |
| Beginning Cash Position | 561,380 | 332,359 | 280,375 | 231,369 | 265,991 |
| End Cash Position | 288,864 | 561,380 | 332,359 | 280,375 | 231,369 |
| Net Cash Flow | $-272,516 | $229,021 | $51,984 | $49,006 | $-34,622 |
| Free Cash Flow | |||||
| Operating Cash Flow | 107,505 | -160,869 | -124,508 | -70,062 | -62,148 |
| Capital Expenditure | -1,551 | -1,931 | -2,464 | -1,241 | -1,024 |
| Free Cash Flow | 105,954 | -162,800 | -126,972 | -71,303 | -63,172 |